Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats

► Intranigral and intrastriatal injection of proteasome inhibitor lactacystin on key markers of PD. ► Intranigral injection of this compound evokes loss of DA in the striatum. ► Such treatment decreases TH and α-synuclein proteins levels in the substantia nigra. ► Intrastriatal injections of this co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurochemistry international 2011-06, Vol.58 (7), p.839-849
Hauptverfasser: Lorenc-Koci, Elżbieta, Lenda, Tomasz, Antkiewicz-Michaluk, Lucyna, Wardas, Jadwiga, Domin, Helena, Śmiałowska, Maria, Konieczny, Jolanta
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 849
container_issue 7
container_start_page 839
container_title Neurochemistry international
container_volume 58
creator Lorenc-Koci, Elżbieta
Lenda, Tomasz
Antkiewicz-Michaluk, Lucyna
Wardas, Jadwiga
Domin, Helena
Śmiałowska, Maria
Konieczny, Jolanta
description ► Intranigral and intrastriatal injection of proteasome inhibitor lactacystin on key markers of PD. ► Intranigral injection of this compound evokes loss of DA in the striatum. ► Such treatment decreases TH and α-synuclein proteins levels in the substantia nigra. ► Intrastriatal injections of this compound did not evoke these effects. ► DA neurons in the SN but not striatal DA terminals are susceptible to proteasome inhibition. Impairment of the ubiquitin-proteasome system, responsible for clearing of misfolded and unwanted proteins, has been implicated in the loss of nigrostriatal dopaminergic neurons characteristic of Parkinson's disease (PD). Recently, proteasome inhibitors have been used to model parkinsonian-like changes in animals. In the present study, the effects of intrastriatal and intranigral injections of the selective proteasome inhibitor lactacystin on key markers of PD were examined in Wistar rats. Comparisons of these two different routes of lactacystin administration revealed that only a unilateral, intranigral injection of lactacystin at a dose of 0.5, 1, 2.5 and 5 μg/2 μl produced after 7 days distinct decreases in the concentrations of dopamine (DA) and its metabolites (DOPAC, 3-MT, HVA) in the ipsilateral striatum. The used doses of lactacystin (except for 0.5 μg/2 μl) significantly accelerated DA catabolism, i.e. the total, oxidative MAO-dependent and COMT-catalyzed pathways, as assessed by HVA/DA, DOPAC/DA and 3-MT/DA ratios, respectively, in the ipsilateral striatum. Such alterations were not observed in the striatal DA content and catabolism either 7, 14 or 21 days after a unilateral, intrastriatal high-dose lactacystin injection (5 and 10 μg/2 μl). Intranigrally administered lactacystin (1 μg/2 μl) caused a marked decline of tyrosine hydroxylase (TH) and α-synuclein protein levels in that structure. Neither TH nor α-synuclein protein levels in the substantia nigra (SN) were affected by high lactacystin doses injected intrastriatally. Moreover, stereological counting of TH-immunoreactive neurons and autoradiographic analysis of [ 3H]GBR 12,935 binding to dopamine transporter confirmed a loss of nigrostriatal dopaminergic neurons after an intranigral lactacystin (1 and 2.5 μg/2 μl) injection. An appearance of cardinal neurochemical and histological changes of parkinsonian type only after intranigral lactacystin injection indicates that DA cell bodies in the SN, but not DA terminals in the striatum are susceptible to proteasome inhibi
doi_str_mv 10.1016/j.neuint.2011.03.013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_874182662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197018611001069</els_id><sourcerecordid>874182662</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-e3ec74b5bd543d056f1bb004c54a1272e491313009faaf81e4e409857d855d493</originalsourceid><addsrcrecordid>eNp9kt-O1CAUxonRuLOrb2BMb8zuTSu0UNobE7P-TTbRC70mFE53GFsYgTGZV_PpPJ2OerdXcE5-fN-BD0JeMFoxytrXu8rDwflc1ZSxijYVZc0jsmGdrMteCv6YbCjrZUlZ116Qy5R2lFLZU_GUXNSMs551YkN-v3PjCBF8LgA3JqcijAXKRu3dfdRTob1d65Sj03np2Nl5h6XOLviFz1so9jFk0CnMgPjWDS6HWEzaZG2OKTvkfJGPe2dQASePwWxhPlWLwxb1whTuT41Zxx8QT5N8xa3zKfjrVFiX0GCRL9A6PSNPRj0leH5er8j3D--_3X4q7758_Hz79q40vOa5hAaM5IMYrOCNpaId2TBQyo3gmtWyBt6zhjWU9qPWY8eAA6d9J6TthLC8b67I9aqLN_x5gJTV7JKBadIewiGpTnLW1W1bI3nzIIl2TdtjBIsoX1ETQ0oRRrWPDu99VIyqJV-1U2u-aslX0UZhvnjs5dnhMMxg_x36GygCr86ATviUI8ZoXPrPcSal6Dhyb1YO8OV-OYgqGQfegHURf4GywT08yR9JJMpw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273699059</pqid></control><display><type>article</type><title>Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lorenc-Koci, Elżbieta ; Lenda, Tomasz ; Antkiewicz-Michaluk, Lucyna ; Wardas, Jadwiga ; Domin, Helena ; Śmiałowska, Maria ; Konieczny, Jolanta</creator><creatorcontrib>Lorenc-Koci, Elżbieta ; Lenda, Tomasz ; Antkiewicz-Michaluk, Lucyna ; Wardas, Jadwiga ; Domin, Helena ; Śmiałowska, Maria ; Konieczny, Jolanta</creatorcontrib><description>► Intranigral and intrastriatal injection of proteasome inhibitor lactacystin on key markers of PD. ► Intranigral injection of this compound evokes loss of DA in the striatum. ► Such treatment decreases TH and α-synuclein proteins levels in the substantia nigra. ► Intrastriatal injections of this compound did not evoke these effects. ► DA neurons in the SN but not striatal DA terminals are susceptible to proteasome inhibition. Impairment of the ubiquitin-proteasome system, responsible for clearing of misfolded and unwanted proteins, has been implicated in the loss of nigrostriatal dopaminergic neurons characteristic of Parkinson's disease (PD). Recently, proteasome inhibitors have been used to model parkinsonian-like changes in animals. In the present study, the effects of intrastriatal and intranigral injections of the selective proteasome inhibitor lactacystin on key markers of PD were examined in Wistar rats. Comparisons of these two different routes of lactacystin administration revealed that only a unilateral, intranigral injection of lactacystin at a dose of 0.5, 1, 2.5 and 5 μg/2 μl produced after 7 days distinct decreases in the concentrations of dopamine (DA) and its metabolites (DOPAC, 3-MT, HVA) in the ipsilateral striatum. The used doses of lactacystin (except for 0.5 μg/2 μl) significantly accelerated DA catabolism, i.e. the total, oxidative MAO-dependent and COMT-catalyzed pathways, as assessed by HVA/DA, DOPAC/DA and 3-MT/DA ratios, respectively, in the ipsilateral striatum. Such alterations were not observed in the striatal DA content and catabolism either 7, 14 or 21 days after a unilateral, intrastriatal high-dose lactacystin injection (5 and 10 μg/2 μl). Intranigrally administered lactacystin (1 μg/2 μl) caused a marked decline of tyrosine hydroxylase (TH) and α-synuclein protein levels in that structure. Neither TH nor α-synuclein protein levels in the substantia nigra (SN) were affected by high lactacystin doses injected intrastriatally. Moreover, stereological counting of TH-immunoreactive neurons and autoradiographic analysis of [ 3H]GBR 12,935 binding to dopamine transporter confirmed a loss of nigrostriatal dopaminergic neurons after an intranigral lactacystin (1 and 2.5 μg/2 μl) injection. An appearance of cardinal neurochemical and histological changes of parkinsonian type only after intranigral lactacystin injection indicates that DA cell bodies in the SN, but not DA terminals in the striatum are susceptible to proteasome inhibition.</description><identifier>ISSN: 0197-0186</identifier><identifier>EISSN: 1872-9754</identifier><identifier>DOI: 10.1016/j.neuint.2011.03.013</identifier><identifier>PMID: 21419185</identifier><identifier>CODEN: NEUIDS</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Acetylcysteine - administration &amp; dosage ; Acetylcysteine - analogs &amp; derivatives ; Acetylcysteine - pharmacology ; Animal model of Parkinson's disease ; Animals ; Binding of [ 3H]GBR 12,935 to DAT ; Biological and medical sciences ; Blotting, Western ; Corpus Striatum - drug effects ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dopamine metabolism ; Dose-Response Relationship, Drug ; Fundamental and applied biological sciences. Psychology ; Intrastriatal and intranigral administration of selective proteasome inhibitor lactacystin ; Male ; Medical sciences ; Neurology ; Parkinson Disease - metabolism ; Proteasome Inhibitors - administration &amp; dosage ; Proteasome Inhibitors - pharmacology ; Rats ; Rats, Wistar ; Substantia Nigra - drug effects ; TH-immunocytochemistry and cresyl violet staining of the substantia nigra ; Vertebrates: nervous system and sense organs ; Western blots of TH and α-synuclein proteins in the substantia nigra</subject><ispartof>Neurochemistry international, 2011-06, Vol.58 (7), p.839-849</ispartof><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-e3ec74b5bd543d056f1bb004c54a1272e491313009faaf81e4e409857d855d493</citedby><cites>FETCH-LOGICAL-c424t-e3ec74b5bd543d056f1bb004c54a1272e491313009faaf81e4e409857d855d493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0197018611001069$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24177584$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21419185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lorenc-Koci, Elżbieta</creatorcontrib><creatorcontrib>Lenda, Tomasz</creatorcontrib><creatorcontrib>Antkiewicz-Michaluk, Lucyna</creatorcontrib><creatorcontrib>Wardas, Jadwiga</creatorcontrib><creatorcontrib>Domin, Helena</creatorcontrib><creatorcontrib>Śmiałowska, Maria</creatorcontrib><creatorcontrib>Konieczny, Jolanta</creatorcontrib><title>Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats</title><title>Neurochemistry international</title><addtitle>Neurochem Int</addtitle><description>► Intranigral and intrastriatal injection of proteasome inhibitor lactacystin on key markers of PD. ► Intranigral injection of this compound evokes loss of DA in the striatum. ► Such treatment decreases TH and α-synuclein proteins levels in the substantia nigra. ► Intrastriatal injections of this compound did not evoke these effects. ► DA neurons in the SN but not striatal DA terminals are susceptible to proteasome inhibition. Impairment of the ubiquitin-proteasome system, responsible for clearing of misfolded and unwanted proteins, has been implicated in the loss of nigrostriatal dopaminergic neurons characteristic of Parkinson's disease (PD). Recently, proteasome inhibitors have been used to model parkinsonian-like changes in animals. In the present study, the effects of intrastriatal and intranigral injections of the selective proteasome inhibitor lactacystin on key markers of PD were examined in Wistar rats. Comparisons of these two different routes of lactacystin administration revealed that only a unilateral, intranigral injection of lactacystin at a dose of 0.5, 1, 2.5 and 5 μg/2 μl produced after 7 days distinct decreases in the concentrations of dopamine (DA) and its metabolites (DOPAC, 3-MT, HVA) in the ipsilateral striatum. The used doses of lactacystin (except for 0.5 μg/2 μl) significantly accelerated DA catabolism, i.e. the total, oxidative MAO-dependent and COMT-catalyzed pathways, as assessed by HVA/DA, DOPAC/DA and 3-MT/DA ratios, respectively, in the ipsilateral striatum. Such alterations were not observed in the striatal DA content and catabolism either 7, 14 or 21 days after a unilateral, intrastriatal high-dose lactacystin injection (5 and 10 μg/2 μl). Intranigrally administered lactacystin (1 μg/2 μl) caused a marked decline of tyrosine hydroxylase (TH) and α-synuclein protein levels in that structure. Neither TH nor α-synuclein protein levels in the substantia nigra (SN) were affected by high lactacystin doses injected intrastriatally. Moreover, stereological counting of TH-immunoreactive neurons and autoradiographic analysis of [ 3H]GBR 12,935 binding to dopamine transporter confirmed a loss of nigrostriatal dopaminergic neurons after an intranigral lactacystin (1 and 2.5 μg/2 μl) injection. An appearance of cardinal neurochemical and histological changes of parkinsonian type only after intranigral lactacystin injection indicates that DA cell bodies in the SN, but not DA terminals in the striatum are susceptible to proteasome inhibition.</description><subject>Acetylcysteine - administration &amp; dosage</subject><subject>Acetylcysteine - analogs &amp; derivatives</subject><subject>Acetylcysteine - pharmacology</subject><subject>Animal model of Parkinson's disease</subject><subject>Animals</subject><subject>Binding of [ 3H]GBR 12,935 to DAT</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Corpus Striatum - drug effects</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dopamine metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Intrastriatal and intranigral administration of selective proteasome inhibitor lactacystin</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neurology</subject><subject>Parkinson Disease - metabolism</subject><subject>Proteasome Inhibitors - administration &amp; dosage</subject><subject>Proteasome Inhibitors - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Substantia Nigra - drug effects</subject><subject>TH-immunocytochemistry and cresyl violet staining of the substantia nigra</subject><subject>Vertebrates: nervous system and sense organs</subject><subject>Western blots of TH and α-synuclein proteins in the substantia nigra</subject><issn>0197-0186</issn><issn>1872-9754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kt-O1CAUxonRuLOrb2BMb8zuTSu0UNobE7P-TTbRC70mFE53GFsYgTGZV_PpPJ2OerdXcE5-fN-BD0JeMFoxytrXu8rDwflc1ZSxijYVZc0jsmGdrMteCv6YbCjrZUlZ116Qy5R2lFLZU_GUXNSMs551YkN-v3PjCBF8LgA3JqcijAXKRu3dfdRTob1d65Sj03np2Nl5h6XOLviFz1so9jFk0CnMgPjWDS6HWEzaZG2OKTvkfJGPe2dQASePwWxhPlWLwxb1whTuT41Zxx8QT5N8xa3zKfjrVFiX0GCRL9A6PSNPRj0leH5er8j3D--_3X4q7758_Hz79q40vOa5hAaM5IMYrOCNpaId2TBQyo3gmtWyBt6zhjWU9qPWY8eAA6d9J6TthLC8b67I9aqLN_x5gJTV7JKBadIewiGpTnLW1W1bI3nzIIl2TdtjBIsoX1ETQ0oRRrWPDu99VIyqJV-1U2u-aslX0UZhvnjs5dnhMMxg_x36GygCr86ATviUI8ZoXPrPcSal6Dhyb1YO8OV-OYgqGQfegHURf4GywT08yR9JJMpw</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Lorenc-Koci, Elżbieta</creator><creator>Lenda, Tomasz</creator><creator>Antkiewicz-Michaluk, Lucyna</creator><creator>Wardas, Jadwiga</creator><creator>Domin, Helena</creator><creator>Śmiałowska, Maria</creator><creator>Konieczny, Jolanta</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20110601</creationdate><title>Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats</title><author>Lorenc-Koci, Elżbieta ; Lenda, Tomasz ; Antkiewicz-Michaluk, Lucyna ; Wardas, Jadwiga ; Domin, Helena ; Śmiałowska, Maria ; Konieczny, Jolanta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-e3ec74b5bd543d056f1bb004c54a1272e491313009faaf81e4e409857d855d493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Acetylcysteine - administration &amp; dosage</topic><topic>Acetylcysteine - analogs &amp; derivatives</topic><topic>Acetylcysteine - pharmacology</topic><topic>Animal model of Parkinson's disease</topic><topic>Animals</topic><topic>Binding of [ 3H]GBR 12,935 to DAT</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Corpus Striatum - drug effects</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dopamine metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Intrastriatal and intranigral administration of selective proteasome inhibitor lactacystin</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neurology</topic><topic>Parkinson Disease - metabolism</topic><topic>Proteasome Inhibitors - administration &amp; dosage</topic><topic>Proteasome Inhibitors - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Substantia Nigra - drug effects</topic><topic>TH-immunocytochemistry and cresyl violet staining of the substantia nigra</topic><topic>Vertebrates: nervous system and sense organs</topic><topic>Western blots of TH and α-synuclein proteins in the substantia nigra</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lorenc-Koci, Elżbieta</creatorcontrib><creatorcontrib>Lenda, Tomasz</creatorcontrib><creatorcontrib>Antkiewicz-Michaluk, Lucyna</creatorcontrib><creatorcontrib>Wardas, Jadwiga</creatorcontrib><creatorcontrib>Domin, Helena</creatorcontrib><creatorcontrib>Śmiałowska, Maria</creatorcontrib><creatorcontrib>Konieczny, Jolanta</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Neurochemistry international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lorenc-Koci, Elżbieta</au><au>Lenda, Tomasz</au><au>Antkiewicz-Michaluk, Lucyna</au><au>Wardas, Jadwiga</au><au>Domin, Helena</au><au>Śmiałowska, Maria</au><au>Konieczny, Jolanta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats</atitle><jtitle>Neurochemistry international</jtitle><addtitle>Neurochem Int</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>58</volume><issue>7</issue><spage>839</spage><epage>849</epage><pages>839-849</pages><issn>0197-0186</issn><eissn>1872-9754</eissn><coden>NEUIDS</coden><abstract>► Intranigral and intrastriatal injection of proteasome inhibitor lactacystin on key markers of PD. ► Intranigral injection of this compound evokes loss of DA in the striatum. ► Such treatment decreases TH and α-synuclein proteins levels in the substantia nigra. ► Intrastriatal injections of this compound did not evoke these effects. ► DA neurons in the SN but not striatal DA terminals are susceptible to proteasome inhibition. Impairment of the ubiquitin-proteasome system, responsible for clearing of misfolded and unwanted proteins, has been implicated in the loss of nigrostriatal dopaminergic neurons characteristic of Parkinson's disease (PD). Recently, proteasome inhibitors have been used to model parkinsonian-like changes in animals. In the present study, the effects of intrastriatal and intranigral injections of the selective proteasome inhibitor lactacystin on key markers of PD were examined in Wistar rats. Comparisons of these two different routes of lactacystin administration revealed that only a unilateral, intranigral injection of lactacystin at a dose of 0.5, 1, 2.5 and 5 μg/2 μl produced after 7 days distinct decreases in the concentrations of dopamine (DA) and its metabolites (DOPAC, 3-MT, HVA) in the ipsilateral striatum. The used doses of lactacystin (except for 0.5 μg/2 μl) significantly accelerated DA catabolism, i.e. the total, oxidative MAO-dependent and COMT-catalyzed pathways, as assessed by HVA/DA, DOPAC/DA and 3-MT/DA ratios, respectively, in the ipsilateral striatum. Such alterations were not observed in the striatal DA content and catabolism either 7, 14 or 21 days after a unilateral, intrastriatal high-dose lactacystin injection (5 and 10 μg/2 μl). Intranigrally administered lactacystin (1 μg/2 μl) caused a marked decline of tyrosine hydroxylase (TH) and α-synuclein protein levels in that structure. Neither TH nor α-synuclein protein levels in the substantia nigra (SN) were affected by high lactacystin doses injected intrastriatally. Moreover, stereological counting of TH-immunoreactive neurons and autoradiographic analysis of [ 3H]GBR 12,935 binding to dopamine transporter confirmed a loss of nigrostriatal dopaminergic neurons after an intranigral lactacystin (1 and 2.5 μg/2 μl) injection. An appearance of cardinal neurochemical and histological changes of parkinsonian type only after intranigral lactacystin injection indicates that DA cell bodies in the SN, but not DA terminals in the striatum are susceptible to proteasome inhibition.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>21419185</pmid><doi>10.1016/j.neuint.2011.03.013</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0197-0186
ispartof Neurochemistry international, 2011-06, Vol.58 (7), p.839-849
issn 0197-0186
1872-9754
language eng
recordid cdi_proquest_miscellaneous_874182662
source MEDLINE; Elsevier ScienceDirect Journals
subjects Acetylcysteine - administration & dosage
Acetylcysteine - analogs & derivatives
Acetylcysteine - pharmacology
Animal model of Parkinson's disease
Animals
Binding of [ 3H]GBR 12,935 to DAT
Biological and medical sciences
Blotting, Western
Corpus Striatum - drug effects
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Dopamine metabolism
Dose-Response Relationship, Drug
Fundamental and applied biological sciences. Psychology
Intrastriatal and intranigral administration of selective proteasome inhibitor lactacystin
Male
Medical sciences
Neurology
Parkinson Disease - metabolism
Proteasome Inhibitors - administration & dosage
Proteasome Inhibitors - pharmacology
Rats
Rats, Wistar
Substantia Nigra - drug effects
TH-immunocytochemistry and cresyl violet staining of the substantia nigra
Vertebrates: nervous system and sense organs
Western blots of TH and α-synuclein proteins in the substantia nigra
title Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A54%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20effects%20of%20intranigral%20and%20intrastriatal%20administration%20of%20the%20proteasome%20inhibitor%20lactacystin%20on%20typical%20neurochemical%20and%20histological%20markers%20of%20Parkinson's%20disease%20in%20rats&rft.jtitle=Neurochemistry%20international&rft.au=Lorenc-Koci,%20El%C5%BCbieta&rft.date=2011-06-01&rft.volume=58&rft.issue=7&rft.spage=839&rft.epage=849&rft.pages=839-849&rft.issn=0197-0186&rft.eissn=1872-9754&rft.coden=NEUIDS&rft_id=info:doi/10.1016/j.neuint.2011.03.013&rft_dat=%3Cproquest_cross%3E874182662%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273699059&rft_id=info:pmid/21419185&rft_els_id=S0197018611001069&rfr_iscdi=true